Clinical Trials Browser

Phase 2/3 × Has announcements × Emapalumab × Clear all

NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Phase 2/3 Completed

45 enrolled 20 charts 1 FDA

Lymphohistiocytosis, Hemophagocytic